Recent studies have shown IVC filters are effective in preventing clinically significant compound inhibitor pulmonary embolism (PE), but have not documented

the frequency of all emboli prevented.\n\nMethods: Patients undergoing major spinal surgery from 2006 to 2009, having IVC filters placed for VTE prophylaxis, were reviewed. Patients with 2 or more risk factors for VTE were included and their perioperative courses were reviewed for PE and device-related complications. Cavograms obtained at the time of attempted filter retrieval identified intercepted emboli. The rates of intercepted emboli and clinical PEs were compared with those of similar populations undergoing similar procedures.\n\nResults: Approximately 17% of patients had entrapped thrombus present at attempted CP-868596 in vivo filter retrieval. An additional 17% of filters were unable to be retrieved due to change in position within the IVC. No patients experienced symptomatic PE. One patient developed a deep vein thrombus requiring pharmacologic treatment and another

patient developed superficial phlebitis. There were no complications related to IVC filter use.\n\nConclusions: These findings show that the decreased rate of PE observed in this and other series is likely because of the use of IVC filters, rather than sampling bias inherent when studying a relatively rare problem. The safety of IVC filters in this population is also confirmed. The observed rate of clinical PE is consistent with other published series. Emboli intercepted by filters may more accurately estimate clinically significant emboli prevented. Therefore, cavograms may prove to be a valuable method of assessing the efficacy of these devices in future studies.”
“Background: Radiation

fibrosis is not easily measurable although clinical scores have been developed for this purpose. Biomarkers present an alternative more objective approach to quantification, and estimation in blood provides accessible samples. We investigated Androgen Receptor Antagonist supplier if blood cytokines could be used to measure established fibrosis in patients who have undergone radiotherapy for breast cancer. Methods: We studied two cohorts treated by breast-conserving surgery and radiotherapy in the UK START Trial A, one with breast fibrosis (cases) and one with no or minimal fibrosis (controls). Two candidate cytokines, plasma connective tissue growth factor (CTGF) and serum interleukin-6 (IL6) were estimated by ELISA. Comparisons between cases and controls used the t-test or Mann-Whitney test and associations between blood concentration and clinical factors were assessed using the Spearman rank correlation coefficient. Results: Seventy patients were included (26 cases, 44 controls). Mean time since radiotherapy was 9.9 years (range 8.3-12.0). No statistically significant differences between cases and controls in serum IL6 (median (IQR) 0.84 pg/ml (0.57-1.14), 0.75 pg/ml (0.41-1.43) respectively) or plasma CTGF (331.